Intraarticular injection of anti-tumor necrosis factor: Comment on the letter by Arnold et al.
Bliddal
Henning
H
D018501:Antirheumatic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001168:Arthritis / Q000188:drug therapy*; D004342:Drug Hypersensitivity; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage* / Q000009:adverse effects; D007270:Injections, Intra-Articular; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept